Notably, targeting VGLL3, either by genetic deletion in mouse placentas or through therapeutic inhibition in human placentas, protects against preeclampsia and alleviates disease pathology.<h4>Conclusions</h4>These findings position VGLL3 as a promising novel therapeutic target for preeclampsia. The gene discussed is VGLL3; the disease is preeclampsia.